Neuroptix, an Acton company developing technology to detect Alzheimer’s through laser eye scanning, announced that they have successfully closed its Series A funding round for a total of $1.6 million.
This round of funding will help the company further commercialize its diagnostic platform, which consists of a laser eye scanning device combined with an eye drop that ID’s Alzheimer’s-related proteins found in the lens of the eye.
The investment was led by Launchpad Venture Group, a Boston-based angel investment group that provides funding to early-stage companies. Said Hambleton Lord, managing director of Launchpad Venture Group: “Launchpad Venture Group and our investor syndicate is pleased to support Neuroptix and its very promising predictive diagnostic technology for a destructive and complex disease like Alzheimer’s. We’re looking forward to continued technological and business development success.”
Participants in the financing included Launchpad Ventures, Maine Angels, and Quan Ventures (Geneva, Switzerland), a group of international investors.
